title: Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.
abstract: The objective of this phase II study was to evaluate the efficacy and toxicity of carboplatin and weekly paclitaxel combination chemotherapy in previously untreated, advanced non-small cell lung cancer (NSCLC). Patients received paclitaxel at a dose of 70 mg/m(2) on days 1, 8, 15, and carboplatin with the target dose of area under the curve (AUC) of 6 on day 1 every 28 days. Forty-six patients were enrolled. A median of four cycles (range, 1-13) were administered. Complete response was observed in one patient (2.2%) and partial response in 23 patients (50%), yielding an overall intent-to-treat response rate of 52.2% (95% confidence interval, 37.8-66.6%). The median survival time was 395 days and 1-year survival rate was 51.4%. Toxicities were mild. Twelve patients (26%) had grade 3 and three patients (7%) had grade 4 neutropenia. Grade 3 thrombocytopenia was seen in four patients (8%). Massive hematoemesis due to duodenal ulcer was observed in one patient, but no other patients experienced grade 3 or more non-hematological toxicities. There was no treatment-related death. Carboplatin and weekly paclitaxel combination chemotherapy is an efficacious and feasible regimen in patients with advanced NSCLC, and this treatment will be a reasonable alternative to the conventional triweekly regimen of paclitaxel and carboplatin.
authors.affiliation: Department of Respiratory Diseases, Hyogo Prefectural Tsukaguchi Hospital, 6-8-17 Minami-tsukaguchi-cho, Amagasaki, Hyogo 661-0012, Japan.
authors.forename: Masataka
authors.initials: M
authors.lastname: Hirabayashi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Endoh
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Teramachi
authors.forename: Masato
authors.initials: M
authors.lastname: Okuda
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: Kohji
authors.initials: K
authors.lastname: Fukuda
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Tokuhisa
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kagioka
authors.forename: Naoharu
authors.initials: N
authors.lastname: Nakai
authors.forename: Masaharu
authors.initials: M
authors.lastname: Nakade
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel